Thursday, December 19, 2013
Publication and contact
c-Ros proto-oncogene 1
receptor tyrosine kinase (ROS1)
Mouse and cell culture
studies suggest foretinib
could help treat cancers harboring oncogenic ROS1 fusions and point
mutations. In multiple cancer cell lines and in a mouse cholangiocarcinoma
model expressing an oncogenic Ros1 variant, foretinib suppressed tumor cell
proliferation more efficiently than the anaplastic
lymphoma kinase (ALK)
which also is known to inhibit ROS1. Cancer cells expressing ROS1-mutant
proteins resistant to Xalkori were sensitive to foretinib. Next steps include
evaluating foretinib in a clinical trial in patients with lung cancer
carrying ROS1 fusions, including patients with crizotinib-resistant tumors.
The trial is being designed by GlaxoSmithKline
plc in partnership with the Oregon
Health & Science University.
GSK's foretinib (GSK1363089)
is in Phase I/II testing to treat breast, liver, non-small cell lung and
Pfizer Inc. markets Xalkori
to treat non-small cell lung cancers (NSCLCs) carrying ALK fusions.
Published online Dec. 19, 2013
Patent filed by OHSU;
licensing details available from OHSU
M.A. et al. Proc. Natl. Acad. Sci. USA; published online Nov. 11,
Contact: Brian J. Druker, Oregon Health &
Science University, Portland, Ore.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]